SAN DIEGO--(BUSINESS WIRE)-- BioLegend, Inc., a provider of antibodies and reagents for biomedical research, announced today the release of over fifty Brilliant Violet 421™ antibody conjugates for use in flow cytometry and microscopy. BioLegend developed these reagents using Brilliant Violet 421™, the first in a series of novel polymer-based fluorophores developed by Sirigen from Nobel Prize-winning chemistry. It is excited by the 405 nm violet laser, and detected with the 450/50 nm filter typically used for Pacific Blue™ and BD Horizon™ V450. Brilliant Violet 421™ antibodies provide exceptional brightness, stability, reliability, and improved signal-to-noise over Pacific Blue™ by 10-fold or more.
“Brilliant Violet 421™ will enable researchers to more clearly resolve populations in multi-color flow cytometry analysis,” said Gene Lay, CEO of BioLegend. “The brightness of BV421™ is on par with that of PE, providing an excellent dynamic range and making it a new first choice for researchers using the violet laser.”
Brilliant Violet 421™ antibodies are fully compatible with currently used buffers and fixatives, and common cell staining techniques, suitable for both surface and intracellular staining of antigens. Its narrow excitation and emission spectra result in less requirement for cross-beam compensation and compensation into neighboring detectors. BioLegend plans to continue to expand this product line, providing more antibody specificities for mouse, rat and human research. For more information, visit www.biolegend.com/brilliantviolet.
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services including assay development, sample testing, and conjugation. BioLegend was incorporated in June, 2002 with headquarters in San Diego, CA.
Dzung Nguyen, Associate Director, Technical Marketing
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Stem Cells Health Biotechnology Clinical Trials Hospitals Medical Devices Oncology Pharmaceutical Radiology Research Other Science Science